MX2020004580A - Azabiciclo y derivados de diazepina para tratar trastornos oculares. - Google Patents

Azabiciclo y derivados de diazepina para tratar trastornos oculares.

Info

Publication number
MX2020004580A
MX2020004580A MX2020004580A MX2020004580A MX2020004580A MX 2020004580 A MX2020004580 A MX 2020004580A MX 2020004580 A MX2020004580 A MX 2020004580A MX 2020004580 A MX2020004580 A MX 2020004580A MX 2020004580 A MX2020004580 A MX 2020004580A
Authority
MX
Mexico
Prior art keywords
azabicyclo
treating ocular
diazepine derivatives
ocular disorders
present
Prior art date
Application number
MX2020004580A
Other languages
English (en)
Inventor
David Ellis
Howard Allen Ketelson
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of MX2020004580A publication Critical patent/MX2020004580A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación provee en un aspecto, derivados de azabiciclo y diazepina útiles como moduladores de receptores muscarínicos. En otro aspecto, la presente invención proporciona composiciones farmacéuticas para tratar enfermedades oculares, las composiciones comprenden al menos un modulador del receptor muscarínico.
MX2020004580A 2017-11-03 2018-11-02 Azabiciclo y derivados de diazepina para tratar trastornos oculares. MX2020004580A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581073P 2017-11-03 2017-11-03
US201862749610P 2018-10-23 2018-10-23
PCT/IB2018/058631 WO2019087146A1 (en) 2017-11-03 2018-11-02 Azabicyclo and diazepine derivatives for treating ocular disorders

Publications (1)

Publication Number Publication Date
MX2020004580A true MX2020004580A (es) 2020-12-03

Family

ID=64267873

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004580A MX2020004580A (es) 2017-11-03 2018-11-02 Azabiciclo y derivados de diazepina para tratar trastornos oculares.
MX2022011310A MX2022011310A (es) 2017-11-03 2020-07-13 Azabiciclo y derivados de diazepina para tratar trastornos oculares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011310A MX2022011310A (es) 2017-11-03 2020-07-13 Azabiciclo y derivados de diazepina para tratar trastornos oculares.

Country Status (12)

Country Link
US (3) US11306090B2 (es)
EP (1) EP3704117A1 (es)
JP (3) JP7065180B2 (es)
KR (1) KR20200083976A (es)
CN (1) CN111247147A (es)
AU (3) AU2018362010B2 (es)
BR (1) BR112020007744A2 (es)
CA (2) CA3076457C (es)
MX (2) MX2020004580A (es)
SG (1) SG11202002692XA (es)
TW (1) TWI826399B (es)
WO (2) WO2019087146A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022523332A (ja) * 2019-02-01 2022-04-22 アエリエ ファーマシューティカルズ インコーポレイテッド 近視を治療するための化合物、組成物及び方法
US20240099970A1 (en) * 2022-09-11 2024-03-28 Alcon Inc. Aqueous pharmaceutical compositions comprising benzyl atropine and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1165037B (de) 1961-11-21 1964-03-12 Dr. Schwarz Arzneimittelfabrik G.m.b.H., Monheim (RhId.) Verfahren zur Herstellung von Estern quaternärer Atropiniumsalze.
GB994493A (en) 1963-02-06 1965-06-10 Lepetit Spa Tropine derivative
DE1670177A1 (de) 1966-12-28 1970-11-12 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen N-substituierten Noratropiniumsalzen
US5223528A (en) * 1986-03-17 1993-06-29 University Of Florida Anticholinergic compounds, composititons and methods of treatment
NZ529615A (en) 2001-05-25 2005-07-29 Valley Forge Pharmaceuticals Pirenzepine ophthalmic gel
FR2834511B1 (fr) 2002-01-07 2004-02-13 Sanofi Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique
CN1546490A (zh) 2003-12-15 2004-11-17 常俊标 不对称双羟基托品类生物碱及其合成新方法和药物用途
CN1283639C (zh) 2004-06-08 2006-11-08 吴建梅 治疗近视眼的哌仑西平有机酸盐及其滴眼剂
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
CA2822758C (en) 2010-12-22 2018-03-20 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivative and process for preparing the same

Also Published As

Publication number Publication date
JP2022101654A (ja) 2022-07-06
WO2019087149A1 (en) 2019-05-09
US20220267328A1 (en) 2022-08-25
SG11202002692XA (en) 2020-05-28
CA3076457A1 (en) 2019-05-09
US11884666B2 (en) 2024-01-30
US20210179616A1 (en) 2021-06-17
TWI826399B (zh) 2023-12-21
RU2020117733A (ru) 2021-12-03
JP7065180B2 (ja) 2022-05-11
WO2019087146A1 (en) 2019-05-09
AU2021205100B2 (en) 2023-01-05
US11306090B2 (en) 2022-04-19
JP2020536922A (ja) 2020-12-17
CA3076457C (en) 2023-09-19
KR20200083976A (ko) 2020-07-09
EP3704117A1 (en) 2020-09-09
CA3205816A1 (en) 2019-05-09
MX2022011310A (es) 2022-10-07
AU2018362010B2 (en) 2021-05-13
BR112020007744A2 (pt) 2020-10-13
AU2018362010A1 (en) 2020-04-09
CN111247147A (zh) 2020-06-05
TW201922731A (zh) 2019-06-16
AU2021205100A1 (en) 2021-08-12
AU2023202036A1 (en) 2023-05-04
US20240132497A1 (en) 2024-04-25
JP2024041971A (ja) 2024-03-27

Similar Documents

Publication Publication Date Title
NZ737399A (en) Ccr2 modulators
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
EA201791239A8 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
PH12018501731A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2014012945A (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
CR20210615A (es) Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
JOP20210328A1 (ar) مركبات أميدات بيريدين-بيرازولو المستبدلة واستخدامها باعتبارها معدِّلات لمستقبل الغلوتومات &#34;glun2b&#34;
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
WO2014066799A3 (en) Modulators of resistant androgen receptor
MX2023000677A (es) Compuestos moduladores de receptor de estrogeno.
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
MX2022011310A (es) Azabiciclo y derivados de diazepina para tratar trastornos oculares.
CR20200346A (es) Oligonucleótidos para modular la expresión de tmem106b
MX2016002931A (es) Moduladores del receptor x hepatico (lxr).
BR112021014566A2 (pt) Moduladores de gpr35